Abstract: Compounds of formula I, that modulate DCAF15 and induce RBM139 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity and DCAF15 modulation are described herein.

Abstract: This invention provides compositions, compounds, and uses thereof, wherein said compounds comprise a single strand oligonucleotide that may form a short oligonucleotide hairpin or stem loop molecule with self complementary base pairing of less than 12 base pairs that bind to RIG-I and activate the RIG-I pathway.

Abstract: A personal mobility device includes a frame, a plurality of wheels attached to the frame and one or more pneumatic motors. Each of the one or more pneumatic motors has a drive shaft in operative connection with at least one of the plurality of wheels. The personal mobility device further includes at least one tank (that is, a storage container) for storage of a pressurized gas in operative connection with the one or more pneumatic motors to supply pressurized gas to the one or more pneumatic motors and a control system in operative connection with the at least one tank and with the one or more pneumatic motors.

Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Abstract: A toe dynamometer is configured to accurately and precisely measure toe extensor strength. The toe dynamometer includes a platform configured to accommodate a patient's foot, and a sensor assembly comprising a force sensor and a toe cap connected to the force sensor. The force sensor is configured to measure forces applied to the force sensor by toe flexion on the force sensor and from toe extension away on the force sensor through the toe cap.

Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R1, and R4 are as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Abstract: A wearable focal vibration device for providing vibration therapy to a patient includes a control module, a vibration module and a vibration sensor. The vibration module is configured to output a vibration in response to a command signal from the control module. The vibration sensor is configured to output a signal to the control module representative of the vibration measured by the vibration sensor. The wearable focal vibration device may also include a harness for attaching the wearable focal vibration device to the patient. The harness can include a compression mechanism and a compression sensor for ensuring that the focal vibration device is sufficiently and consistently secured to the patient.

Abstract: A wheelchair includes a frame, a seat attached to the frame, a first forward wheel on a first side of the frame and a second forward wheel on a second side of the frame, a first rearward wheel on the first side of the frame and a second rearward wheel on the second side of the frame, a first drive wheel on the first side of the frame positioned intermediate between the first forward wheel and the first rearward wheel and a second drive wheel on the second side of the frame positioned intermediate between the second forward wheel and the second rearward wheel, and actuators to independently control the vertical position of the first forward wheel relative to the frame, the vertical position of the second forward wheel relative to the frame, the vertical position of the first rearward wheel relative to the frame, the vertical position of the second rearward wheel relative to the frame, the vertical position of the first drive wheel relative to the frame and the vertical position of the second drive wheel relati

Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: “Z” and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Abstract: A wheelchair includes a frame, a seat attached to the frame, a first forward wheel on a first side of the frame and a second forward wheel on a second side of the frame, a first rearward wheel on the first side of the frame and a second rearward wheel on the second side of the frame, a first drive wheel on the first side of the frame positioned intermediate between the first forward wheel and the first rearward wheel and a second drive wheel on the second side of the frame positioned intermediate between the second forward wheel and the second rearward wheel, and actuators to independently control the vertical position of the first forward wheel relative to the frame, the vertical position of the second forward wheel relative to the frame, the vertical position of the first rearward wheel relative to the frame, the vertical position of the second rearward wheel relative to the frame, the vertical position of the first drive wheel relative to the frame and the vertical position of the second drive wheel relati

Abstract: A toe dynamometer is configured to accurately and precisely measure toe extensor strength. The toe dynamometer includes a platform configured to accommodate a patient's foot, and a sensor assembly comprising a force sensor and a toe cap connected to the force sensor. The force sensor is configured to measure forces applied to the force sensor by toe flexion on the force sensor and from toe extension away on the force sensor through the toe cap.

Abstract: The present invention relates to biaryl monobactam compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Abstract: The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

Abstract: Disclosed are an intelligent traditional Chinese medicine diagnosis method, system and traditional Chinese medicine system, the method comprising: a server side obtaining, from distributed client clusters, inspection training data, auscultation-olfaction diagnosis training data, interrogation training data and palpation training data of a patient; the server side training, by using the inspection training data, the auscultation-olfaction diagnosis training data, the interrogation training data and the palpation training data, a model to be trained established on the basis of a deep neural network algorithm to obtain a trained model; and the server side using the trained model to perform diagnosis with respect to disease data of the patient to obtain a diagnostic result of the disease data.

Abstract: Embodiments provide methods and systems for modeling the flow of fluid in variable physical and geological environments using dynamically determined Navier-Stokes equations (NSE), such as Darcy Flow and Poiseuille flow.

Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.